Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XP 102

Next Previous
Search
Drug Profile

XP 102

Alternative Names: BI 882370; XP-102

Latest Information Update: 28 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Xynomic Pharmaceuticals
  • Class Antineoplastics; Piperidines; Pyridines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Proto-oncogene protein b-raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Colorectal cancer; Malignant melanoma

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for preclinical development in Colorectal-cancer in Germany (PO)
  • 28 Sep 2023 No recent reports of development identified for preclinical development in Malignant-melanoma in Germany (PO)
  • 11 Mar 2022 Xynomic Pharmaceuticals plans a phase I/IIa ENHANCE trial for Malignant melanoma, Colorectal cancer, Thyroid cancer, Non-small cell lung cancer (Late-stage disease, Combination Therapy, Metastatic disease, Monotherapy) (PO) in June 2022 (NCT05275374)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top